Bevacizumab for Cerebral Radionecrosis: A Single-Center Experience

被引:4
|
作者
Climans, Seth A. [1 ,2 ,3 ,4 ]
Ramos, Ronald C. [1 ,2 ,3 ]
Jablonska, Paola A. [5 ]
Shultz, David B. [5 ]
Mason, Warren P. [1 ,2 ,3 ]
机构
[1] Princess Margaret Canc Ctr, Dept Neurol, Toronto, ON, Canada
[2] Princess Margaret Canc Ctr, Dept Med Oncol, Toronto, ON, Canada
[3] Princess Margaret Canc Ctr, Dept Hematol, Toronto, ON, Canada
[4] London Hlth Sci Ctr, Dept Oncol, London, ON, Canada
[5] Princess Margaret Canc Ctr, Dept Radiat Oncol, Toronto, ON, Canada
关键词
Radiotherapy; Radionecrosis; Bevacizumab; Brain metastasis; Meningioma; RADIATION NECROSIS; SAFETY;
D O I
10.1017/cjn.2022.64
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Cerebral radionecrosis, a subacute or late effect of radiotherapy, can be debilitating and difficult to treat. Steroids can reduce symptoms, but have significant long-term side effects. Bevacizumab has been shown to reduce edema and other radiologic features associated with radionecrosis and improve patient symptoms. We report our experience using bevacizumab for cerebral radionecrosis. Methods: We retrospectively reviewed the charts of all patients treated at our institution with bevacizumab for non-glioma-associated cerebral radionecrosis. We recorded change in symptoms, change in steroids, change in performance status, time to tumor progression, and time to death. We delineated the volume of necrosis pre- and post-bevacizumab on T1-post-gadolinium and fluid-attenuated inversion recovery (FLAIR) MRI scans. Results: We identified 15 patients, 8 with brain metastases, 6 with meningioma, and 1 with nasopharyngeal carcinoma. Most received four doses of bevacizumab, 7.5 mg/kg q 3 weeks x 4 doses. Neuroimaging demonstrated a reduced T1 gadolinium-enhancing volume and edema in 14/15 patients (the average reduction in T1-post-gadolinium volume was 3.0 cm(3), and average reduction in FLAIR volume was 27.9 cm(3)). There was no appreciable change in patient performance status. Steroid doses decreased in five of nine patients. There was a high rate (26%) of adverse events, including pulmonary embolism, stroke, and wound dehiscence. The median progression-free survival was 6.5 months. Conclusion: Although bevacizumab is commonly prescribed for cerebral radionecrosis, in our retrospective cohort, the clinical benefits were modest and there was significant toxicity.
引用
收藏
页码:573 / 578
页数:6
相关论文
共 50 条
  • [21] Endovascular Mechanical Thrombectomy for Cerebral Venous Sinus Thrombosis: A Single-Center Experience
    Styczen, Hanna
    Tsogkas, Ioannis
    Liman, Jan
    Maus, Volker
    Psychogios, Marios Nikos
    WORLD NEUROSURGERY, 2019, 127 : E1097 - E1103
  • [22] Aortic arch vessel stenting - A single-center experience using cerebral protection
    Peterson, Brian G.
    Resnick, Scott A.
    Morasch, Mark D.
    Hassoun, Heitham T.
    Eskandari, Mark K.
    ARCHIVES OF SURGERY, 2006, 141 (06) : 560 - 563
  • [23] Microsurgical clipping of large and giant cerebral aneurysms: A single-center contemporary experience
    Chalouhi, Nohra
    Thakkar, Vismay
    Tjoumakaris, Stavropoula
    Gonzalez, L. Fernando
    Hasan, David
    Rosenwasser, Robert
    Singhal, Saurabh
    Jabbour, Pascal M.
    JOURNAL OF CLINICAL NEUROSCIENCE, 2014, 21 (08) : 1424 - 1427
  • [24] BEVACIZUMAB AND GLIOBASTOMA OF THE ELDERLY: A SINGLE-CENTER RETROSPECTIVE ANALYSIS
    Barrascout, Eduardo
    Lamuraglia, Michele
    Gervais, Claire
    Tiako, Manuela
    Gaillard, Stephan
    Aldea, Sorin
    Mabro, May
    Gachet, Julie
    Theodore, Christine
    NEURO-ONCOLOGY, 2014, 16
  • [25] Laparoscopic Gastrectomy: A Single-Center Experience
    Kowalski, Rebecca
    Montes, Jennifer
    Damani, Tanuja
    Shah, Paresh C.
    GASTROENTEROLOGY, 2011, 140 (05) : S1023 - S1023
  • [26] Single-center experience with the PowerLink device
    Coppi, G
    Gennai, S
    Silingardi, R
    Saitta, G
    JOURNAL OF ENDOVASCULAR THERAPY, 2004, 11 : 13 - 14
  • [27] Thoracic Traumas: A Single-Center Experience
    Ustaalioglu, Recep
    Yildirim, Mehmet
    Cosgun, Hatice
    Dogusoy, Ilgaz
    Imamoglu, Oya
    Yasaroglu, Murat
    Aydemir, Bulent
    Okay, Tamer
    TURKISH THORACIC JOURNAL, 2015, 16 (02) : 59 - 63
  • [28] Secukinumab in psoriasis: A single-center experience
    Agaoglu, Esra
    Erdogan, Hilal Kaya
    Acer, Ersoy
    Saracoglu, Zeynep Nurhan
    Bilgin, Muzaffer
    TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, 2021, 55 (03): : 125 - 129
  • [29] Neuroendocrine tumors:: A single-center experience
    Özdemir, NY
    Öksüzoglu, B
    Budakoglu, B
    Abali, H
    Zengin, N
    NEUROENDOCRINOLOGY, 2006, 83 (01) : 41 - 41
  • [30] Allograft nephrectomy - a single-center experience
    Toth Fruzsina
    Zadori Gergely
    Fedor Roland
    Kovacs David Agoston
    Kanyari Zsolt
    Kincses Zsolt
    Otvos Csaba
    Damjanovich Laszlo
    Asztalos Laszlo
    Nemes Balazs
    ORVOSI HETILAP, 2016, 157 (24) : 964 - 970